Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

Leveraging rapid technological advances for human health is a global trend, driving the rise of biomedical engineering ...

Continuous Glucose Monitoring (CGM) Systems Market The increasing incidence of diabetes and the detection of patient's blood glucose levels are raising the demand for continuous global monitoring ...

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

Senseonics Holdings, Inc. (NYSE: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with ...

Home blood glucose monitoring was first introduced in 1980. While there were initially hurdles to overcome related to accuracy and cost, a consistent hurdle since that time has been efficient data ...

today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better ...